Hugh D. Allen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hugh D. Allen has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Jerry R. Mendell
Wellstone Muscular Dystrophy Cooperative Research Center; Nationwide Children's Hospital; Columbus Ohio USA
4 shared publications- Kevin M. Flanigan
Center for Gene Therapy, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, USA
4 shared publications Philip T. Thrush
The Heart Center, Nationwide Children's Hospital, Columbus, Ohio, USA; Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA
3 shared publicationsAlan Pestronk
Department of Neurology, Washington University, St. Louis, Missouri
1 shared publicationAlbert C. Ludolph
1 shared publicationAli Yilmaz
1 shared publication
Latest Publications
- Open Access
- 30 April 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (5) , 733
Signal-to-Noise Analysis Can Inform the Likelihood That Incidentally Identified Variants in Sarcomeric Genes Are Associated with Pediatric Cardiomyopathy
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy and can predispose individuals to sudden death. Most pediatric HCM patients host a known pathogenic variant in a sarcomeric gene. With the increase in exome sequencing (ES) in clinical settings, incidental variants in HCM-associated genes are being identified more frequently. Diagnostic interpretation of incidental variants is crucial to enhance clinical patient management. We sought to use amino acid-level signal-to-noise (S:N) analysis to establish pathogenic hotspots in sarcomeric HCM-associated genes as well as to refine the 2015 American College of Medical Genetics (ACMG) criteria to predict incidental variant pathogenicity. Methods and Results: Incidental variants in HCM genes (MYBPC3, MYH7, MYL2, MYL3, ACTC1, TPM1, TNNT2, TNNI3, and TNNC1) were obtained from a clinical ES referral database (Baylor Genetics) and compared to rare population variants (gnomAD) and variants from HCM literature cohort studies. A subset of the ES cohort was clinically evaluated at Texas Children’s Hospital. We compared the frequency of ES and HCM variants at specific amino acid locations in coding regions to rare variants (MAF < 0.0001) in gnomAD. S:N ratios were calculated at the gene- and amino acid-level to identify pathogenic hotspots. ES cohort variants were re-classified using ACMG criteria with S:N analysis as a correlate for PM1 criteria, which reduced the burden of variants of uncertain significance. In the clinical validation cohort, the majority of probands with cardiomyopathy or family history hosted likely pathogenic or pathogenic variants. Conclusions: Incidental variants in HCM-associated genes were common among clinical ES referrals, although the majority were not disease-associated. Leveraging amino acid-level S:N as a clinical tool may improve the diagnostic discriminatory ability of ACMG criteria by identifying pathogenic hotspots.
- 30 April 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (5) , 733
Open AccessSignal-to-Noise Analysis Can Inform the Likelihood That Incidentally Identified Variants in Sarcomeric Genes Are Associated with Pediatric Cardiomyopathy
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy and can predispose individuals to sudden death. Most pediatric HCM patients host a known pathogenic variant in a sarcomeric gene. With the increase in exome sequencing (ES) in clinical settings, incidental variants in HCM-associated genes are being identified more frequently. Diagnostic interpretation of incidental variants is crucial to enhance clinical patient management. We sought to use amino acid-level signal-to-noise (S:N) analysis to establish pathogenic hotspots in sarcomeric HCM-associated genes as well as to refine the 2015 American College of Medical Genetics (ACMG) criteria to predict incidental variant pathogenicity. Methods and Results: Incidental variants in HCM genes (MYBPC3, MYH7, MYL2, MYL3, ACTC1, TPM1, TNNT2, TNNI3, and TNNC1) were obtained from a clinical ES referral database (Baylor Genetics) and compared to rare population variants (gnomAD) and variants from HCM literature cohort studies. A subset of the ES cohort was clinically evaluated at Texas Children’s Hospital. We compared the frequency of ES and HCM variants at specific amino acid locations in coding regions to rare variants (MAF < 0.0001) in gnomAD. S:N ratios were calculated at the gene- and amino acid-level to identify pathogenic hotspots. ES cohort variants were re-classified using ACMG criteria with S:N analysis as a correlate for PM1 criteria, which reduced the burden of variants of uncertain significance. In the clinical validation cohort, the majority of probands with cardiomyopathy or family history hosted likely pathogenic or pathogenic variants. Conclusions: Incidental variants in HCM-associated genes were common among clinical ES referrals, although the majority were not disease-associated. Leveraging amino acid-level S:N as a clinical tool may improve the diagnostic discriminatory ability of ACMG criteria by identifying pathogenic hotspots.
- 20 March 2013
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 8 (6) , 561-567
Precordial R Wave Height Does Not Correlate with Echocardiographic Findings in Boys with Duchenne Muscular Dystrophy
Cardiomyopathy (CM) is an inevitable consequence of Duchenne muscular dystrophy, and electrocardiographic changes, right ventricular hypertrophy in particular, have been proposed to serve as an early marker for CM. To evaluate this concept, we assessed the correlation between R wave height in lead V1 and echocardiographic findings in boys with Duchenne muscular dystrophy. Serial echocardiograms and electrocardiograms (n = 800) were performed during each clinic visit in a cohort of 155 boys with Duchenne muscular dystrophy. Precordial R wave height in lead V1 was measured. Echocardiographic parameters included ejection fraction (EF), shortening fraction, and left ventricular end-diastolic dimension. Data were analyzed using Pearson correlation and linear regression. Ages ranged from 1.8 to 37.2 years (mean 14.7 ± 5.9 years). Seventy-one patients had CM and 318/800 echocardiograms had an EF < 55%. Older patients tended to have a lower EF, but there was no correlation between age and left ventricular end-diastolic dimension. R wave height in lead V1 correlated poorly with both left ventricular end-diastolic dimension (r = 0.096, P =.0078) and EF (r = 0.096, P =.0088) for the whole cohort as well as those studies demonstrating an EF <55% (left ventricular end-diastolic dimension r = 0.089, P =.12 and EF r = -0.044, P =.94). No individual patient demonstrated significant correlation between R wave height in lead V1 and left ventricular end-diastolic dimension or EF. Left ventricular end-diastolic dimension showed a moderate negative correlation with EF for the whole cohort (r = -0.394, P <.001) as well as those with an EF < 55% (r = -0.376, P <.001). The precordial R wave height in V1 correlates poorly with the presence of depressed left ventricular function and is not prognostic for the development of CM. While not predictive for CM, the electrocardiogram remains vital to cardiac screening for boys with Duchenne muscular dystrophy due to risk for other cardiac manifestations such as arrhythmias.
- 20 March 2013
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 8 (6) , 561-567
Precordial R Wave Height Does Not Correlate with Echocardiographic Findings in Boys with Duchenne Muscular Dystrophy
Cardiomyopathy (CM) is an inevitable consequence of Duchenne muscular dystrophy, and electrocardiographic changes, right ventricular hypertrophy in particular, have been proposed to serve as an early marker for CM. To evaluate this concept, we assessed the correlation between R wave height in lead V1 and echocardiographic findings in boys with Duchenne muscular dystrophy. Serial echocardiograms and electrocardiograms (n = 800) were performed during each clinic visit in a cohort of 155 boys with Duchenne muscular dystrophy. Precordial R wave height in lead V1 was measured. Echocardiographic parameters included ejection fraction (EF), shortening fraction, and left ventricular end-diastolic dimension. Data were analyzed using Pearson correlation and linear regression. Ages ranged from 1.8 to 37.2 years (mean 14.7 ± 5.9 years). Seventy-one patients had CM and 318/800 echocardiograms had an EF < 55%. Older patients tended to have a lower EF, but there was no correlation between age and left ventricular end-diastolic dimension. R wave height in lead V1 correlated poorly with both left ventricular end-diastolic dimension (r = 0.096, P =.0078) and EF (r = 0.096, P =.0088) for the whole cohort as well as those studies demonstrating an EF <55% (left ventricular end-diastolic dimension r = 0.089, P =.12 and EF r = -0.044, P =.94). No individual patient demonstrated significant correlation between R wave height in lead V1 and left ventricular end-diastolic dimension or EF. Left ventricular end-diastolic dimension showed a moderate negative correlation with EF for the whole cohort (r = -0.394, P <.001) as well as those with an EF < 55% (r = -0.376, P <.001). The precordial R wave height in V1 correlates poorly with the presence of depressed left ventricular function and is not prognostic for the development of CM. While not predictive for CM, the electrocardiogram remains vital to cardiac screening for boys with Duchenne muscular dystrophy due to risk for other cardiac manifestations such as arrhythmias.
- Open Access
- 1 January 2013
- Published by Public Library of Science (PLoS) in PLoS Currents
- Vol. 5
A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy
Objectives: This study sought to compare the effectiveness and safety of an angiotensin converting enzyme inhibitor (ACE-I) (lisinopril) vs. an angiotensin receptor blocker (ARB) (losartan) for the treatment of cardiomyopathy (CM) in boys with Duchenne muscular dystrophy (DMD). Background: Development of CM is universal in boys with DMD. ACE-I and ARB have both been suggested as effective treatment options. ARBs have been associated with skeletal muscle regeneration in a mouse model of DMD. The question of which, if either, is more effective for CM treatment in DMD remains. The purpose of this multicenter double-blind prospective study was to compare efficacy and safety of lisinopril versus losartan in the treatment of newly diagnosed CM in boys with DMD. Methods: Echocardiographic technician inter- and intraobserver variability were tested on 2 separate days on 2 different boys with DMD CM. Results were compared with paired t-testing. Twenty-two boys with newly diagnosed DMD CM (echocardiographic ejection fraction (EF) 10% EF drop. Three boys in the aCE-I group had 3 visits, due to study funding termination. Two were withdrawn because of low EF. All their data are included in the analysis for as long as they remained in the study. Mean EF’s were similar at baseline (47.5%- ACE-I, 48.4%- ARB). After 1 year each group significantly improved to 54.6% and 55.2% respectively (p=.02). There was no difference between the 2 treatment groups at 1 year. Conclusions: Inter-observer and intra-observer reliability studies showed no differences between echocardiographers on serial examinations. EF improved equally in the two groups. There is no therapeutic difference in EF improvement between lisinopril and losartan over the one-year duration for treatment of boys with DMD-related CM. Trial Registration: ClinicalTrials.gov NCT01982695
- 1 January 2013
- Published by Public Library of Science (PLoS) in PLoS Currents
- Vol. 5
Open AccessA Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy
Objectives: This study sought to compare the effectiveness and safety of an angiotensin converting enzyme inhibitor (ACE-I) (lisinopril) vs. an angiotensin receptor blocker (ARB) (losartan) for the treatment of cardiomyopathy (CM) in boys with Duchenne muscular dystrophy (DMD). Background: Development of CM is universal in boys with DMD. ACE-I and ARB have both been suggested as effective treatment options. ARBs have been associated with skeletal muscle regeneration in a mouse model of DMD. The question of which, if either, is more effective for CM treatment in DMD remains. The purpose of this multicenter double-blind prospective study was to compare efficacy and safety of lisinopril versus losartan in the treatment of newly diagnosed CM in boys with DMD. Methods: Echocardiographic technician inter- and intraobserver variability were tested on 2 separate days on 2 different boys with DMD CM. Results were compared with paired t-testing. Twenty-two boys with newly diagnosed DMD CM (echocardiographic ejection fraction (EF) 10% EF drop. Three boys in the aCE-I group had 3 visits, due to study funding termination. Two were withdrawn because of low EF. All their data are included in the analysis for as long as they remained in the study. Mean EF’s were similar at baseline (47.5%- ACE-I, 48.4%- ARB). After 1 year each group significantly improved to 54.6% and 55.2% respectively (p=.02). There was no difference between the 2 treatment groups at 1 year. Conclusions: Inter-observer and intra-observer reliability studies showed no differences between echocardiographers on serial examinations. EF improved equally in the two groups. There is no therapeutic difference in EF improvement between lisinopril and losartan over the one-year duration for treatment of boys with DMD-related CM. Trial Registration: ClinicalTrials.gov NCT01982695
- 1 November 2012
- Published by Elsevier in Physical Medicine and Rehabilitation Clinics of North America
- Vol. 23 (4) , 855-868
Cardiac Management in Neuromuscular Diseases
- 1 November 2012
- Published by Elsevier in Physical Medicine and Rehabilitation Clinics of North America
- Vol. 23 (4) , 855-868
Cardiac Management in Neuromuscular Diseases